Multiple 30-Month Stays Remain Possible Under Waxman/Hatch Reforms
Executive Summary
Multiple 30-month stays on abbreviated new drug applications are still an option in some cases, an FDA 1draft guidance says
You may also be interested in...
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.
Boniva Gets A Second, Truncated 30-Month Stay
Orchid's revised patent certification against the osteoporosis drug ibandronate allows Roche to block approval until March 2012.